Physician profile
Brooke A Kempf
NPI 1316257645
$1,134,056.59
in general payments reported to CMS, 2019-2025
20 companies · $367K in 2025
The $367K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112K · 2022: $143K · 2023: $243K · 2024: $270K · 2025: $367K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $556K · Consulting Fee: $134K · Travel and Lodging: $118K · Honoraria: $41K · Food and Beverage: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,037 · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $555,813.85 |
| Consulting Fee | $134,094.90 |
| Travel and Lodging | $117,793.57 |
| Honoraria | $41,250.00 |
| Food and Beverage | $27,678.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,037.00 |
| Education | $467.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $276,943.50 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227,323.00 | 2021-2025 | Caplyta |
| Alkermes, INC. | $199,981.78 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $195,807.50 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $97,162.67 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $59,901.46 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $42,771.06 | 2021-2023 | Abilify Maintena, Rexulti |
| Luye Pharma (USA) Ltd. | $10,632.74 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $5,713.15 | 2021-2024 | Trintellix |
| Indivior INC. | $4,594.65 | 2021-2024 | Perseris |
| Abbvie INC. | $3,648.90 | 2021-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,571.93 | 2021-2025 | Rexulti |
| Sage Therapeutics, LLC | $2,124.04 | 2023 | |
| Neurocrine Biosciences, INC. | $1,763.15 | 2025 | |
| Janssen Scientific Affairs, LLC | $1,623.87 | 2023-2025 | Spravato, Invega Sustenna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $208.84 | 2021-2023 | Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $127.64 | 2021-2022 | |
| Novo Nordisk INC | $97.20 | 2021 | |
| Tris Pharma INC | $42.97 | 2025 | Onyda Xr, Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $16.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Kempf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.